Application of Individualized Treatment for CLL: Novel Agents, Combinations, and Sequencing Therapy

Application of Individualized Treatment for CLL: Novel Agents, Combinations, and Sequencing Therapy

Friday, December 4, 2020
Webinar -- 7:00 AM PT


Welcome and Introduction (10 min)

Selecting Therapy for Treatment-Naive CLL (30 min)

Selecting Therapy for Previously Treated CLL (30 min)

Near Future Directions: Promising Agents and Combinations Under Investigation (30 min)

Panel Discussion and Audience Question and Answer Session (20 min)


Program Director
William G. Wierda, MD, PhD

Professor of Medicine
Chief, Section of CLL
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jeremy S. Abramson, MD, MMSc

Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts

Brian T. Hill, MD, PhD

Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Goal Statement
The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the use current/emerging therapeutic strategies in the care of their patients with CLL/SLL.

Target Audience
This program is intended for hematologists/oncologists, physician assistants, nurses, pharmacists, and other clinicians involved in the management of patients with chronic lymphocytic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the efficacy and safety of targeted agents and combination regimens indicated for frontline therapy in CLL/SLL
  • Select the optimal treatment for individual patients with newly diagnosed CLL/SLL based on the available clinical data, guidelines, and expert recommendations
  • Apply the totality of clinical data to optimally sequence targeted therapies for the management of patients with CLL/SLL
  • Develop an individualized treatment plan for patients with multiple relapses and resistance or intolerance to BTK inhibitors
  • Evaluate the evolving role of allogeneic hematopoietic cell transplant and chimeric antigen receptor CAR T-cell therapy
  • Develop strategies to address unique challenges (e.g. identification and management of adverse events, adherence/compliance to treatment) as well as improve clinical outcomes and quality of life


Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
NCCN designates this educational activity for a maximum of 2.0 contact hours.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 2.0 contact hour (0.20 CEUs) of continuing education credit. UAN: JA4008196-0000-20-099-L01-P

Attention Pharmacists:
You must complete the posttest and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the posttest and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at to obtain your NABP e-Profile ID.

Physician Assistant Continuing Education
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests by experts on the topics). Full disclosure of faculty relationships will be made prior to the activity.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.